BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, today announced that BriaCell’s clinical findings were
published at the 2019 American Society of Clinical Oncology (ASCO)
Annual Meeting Proceedings, a supplement to the Journal of Clinical
Oncology. ASCO’s Annual Meeting, taking place May 31-June 4, 2019
at the McCormick Place Convention Center in Chicago, IL, represents
the world’s largest gathering of oncology physicians, biotechnology
executives, researchers, and investment analysts to discuss
cutting-edge clinical research and therapeutics in oncology.
Abstract Title: Safety
and efficacy of a phase I/IIa trial (NCT03066947) of a modified
whole tumor cell targeted immunotherapy in patients with advanced
breast cancer
Abstract No:
e14026Citation: J Clin Oncol 37, 2019 (suppl;
abstr e14026)
Clinical data of 23 advanced breast cancer
patients dosed with Bria-IMT™ in the completed Phase I/IIa clinical
study (NCT03066947) showed that Bria-IMT™ immunotherapy treatment
was safe and well-tolerated, and tumor regression was reported in
several advanced breast cancer patients who failed a number of
previous treatments. Importantly, these top-responder patients
matched Bria-IMT™ at specific HLA types, suggesting a unique
mechanism of action for Bria-IMT™ which sets it apart from other
immunotherapy products. The findings have been the basis for the
development of Bria-OTS™, BriaCell’s off-the-shelf personalized
immunotherapy for advanced breast cancer, and BriaDX™, BriaCell’s
companion diagnostic identification test. Bria-OTS™ is
expected to receive FDA approval to begin clinical testing in late
2019.
For the copy of the abstract, please visit:
http://abstracts.asco.org/239/AbstView_239_260919.html.
“Our clinical findings published at the 2019
ASCO meeting have provided new insights into the potential of
Bria-IMT™ immunotherapy to offer clinical benefits to advanced
breast cancer patients, both as monotherapy, and in combination
with other drugs,” stated Dr. Williams, BriaCell’s President and
CEO. “We are excited with the potential clinical benefits of
Bria-IMT™ in combination with pembrolizumab [KEYTRUDA®;
manufactured by Merck & Co., Inc. (NYSE: MRK)], and with
INCMGA00012 and epacadostat [experimental drugs manufactured by
Incyte (NYSE: INCY)] and look forward to sharing additional data in
the second half of 2019.”
Abstract Title: Real-time monitoring of
circulating stromal cells in the blood to predict responsiveness of
new-line therapies in metastatic breast
cancer
Abstract No: e14048Citation: J
Clin Oncol 37, 2019 (suppl; abstr e14048)
BriaCell participated in this prospective
12-month multi-institutional pilot study of cancer associated
macrophage like cells (CAMLs) in the blood of the patients with
advanced breast cancer. The patient’s blood samples were
analyzed to determine the value of CAMLs as an independent
indicator of survival in these patients. The data indicated that
monitoring CAML changes over the initial period of treatment
accurately predicted the responsiveness of patients to experimental
therapy. Hence, the use of blood sampling may predict the clinical
value of the immunotherapy treatment early on and determine the
best course of subsequent treatment for the patient.
For the copy of the abstract, please visit:
http://abstracts.asco.org/239/AbstView_239_264031.html.
“These important findings should help us better
monitor and evaluate the anti-tumor response to Bria-IMT™ in
advanced breast cancer patients, and modify the course of treatment
if necessary,” stated Dr. Lacher, BriaCell’s head of R&D. “We
have seen very intriguing changes in CAMLs in our patients treated
with Bria-IMT™ which may indicate that we are generating potent
immune responses especially in patients who match Bria-IMT™ at
specific HLA types”.
Dr. Charles Wiseman, scientific founder and
director of Briacell, commented, “These very positive results are
tremendously encouraging. We documented actual shrinkage, and
in some tumor sites, complete regression, with few side-effects, in
this Phase I/IIa trial for terminal patients already resistant
to chemotherapy. We have our marching orders to intensify our
research, especially with the opportunity to combine Bria-IMT™ with
some other promising new agents like KEYTRUDA®, INCMGA00012 and
epacadostat.”
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, its lead candidate, in a Combination
Study with KEYTRUDA®. The Combination Study is listed in
ClinicalTrials.gov as NCT03328026.
About American Society of Clinical
Oncology (ASCO) Conference
Founded in 1964, ASCO is the world’s leading
professional organization for physicians, oncology professionals,
and research scientists in the field of oncology. ASCO’s Mission
over the years has been conquering cancer through research,
education, and promotion of the highest quality patient care.
ASCO’s Annual meeting represents the world’s
largest gathering of oncology physicians, biotechnology executives,
researchers, patient advocates, and investment analysts to discuss
cutting-edge clinical research and therapeutics in oncology, and to
gain insights for improving cancer care.
For additional information on the 2019 ASCO’s
Annual meeting, please visit https://www.asco.org/.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a
Combination Study with pembrolizumab [KEYTRUDA®; manufactured by
Merck & Co., Inc. (NYSE: MRK)]. The Combination Study is listed
in ClinicalTrials.gov as NCT03328026.
BriaCell and Incyte Corporation (NASDAQ: INCY)
have formed a non-exclusive clinical trial collaboration to
evaluate the effects of combinations of novel clinical candidates.
Under the agreement, Incyte and BriaCell will be evaluating novel
combinations of compounds from Incyte’s development portfolio with
Bria-IMT™ in advanced breast cancer patients.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2024 to May 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From May 2023 to May 2024